ALK and neuroblastoma: Phase I clinical trials using the second-generation ALK inhibitor ceritinib demonstrated responsiveness in a subset of patients with refractory or relapsed neuroblastoma, with indications that individuals bearing the R1275Q mutation were more sensitive to treatment [107].